Literature DB >> 9659159

Effects of smoking on the urine excretion of oral 51Cr EDTA in ulcerative colitis.

C Benoni1, H Prytz.   

Abstract

BACKGROUND: Smokers have a reduced risk and ex-smokers an increased risk of ulcerative colitis (UC). Stopping smoking often precedes onset and relapses. Smoking reduces the 24 hour urine excretion of oral chromium-51 labelled EDTA in healthy individuals. AIMS: To estimate the effects of smoking on the urine excretion of oral 51Cr EDTA in well characterised patients with UC.
SUBJECTS: Sixteen smoking and 16 non-smoking patients with UC in remission were studied. The non-smokers had never smoked. Most were taking 5-aminosalicylic acid. No patient took steroids or immunosuppressants. The control group comprised 25 smoking healthy volunteers and 25 who had never smoked. The median cigarette consumption was equal in the patients and volunteers.
METHODS: The 24 hour urine excretion of oral 51Cr EDTA was measured and the results were correlated with smoking habits, number of cigarettes, and disease extent.
RESULTS: Patients with UC had significantly higher 24 hour urine recoveries than healthy controls (p = 0.04). This difference was more pronounced when patients who smoked were compared with healthy smokers (p = 0.005) No significant differences were found when comparing non-smoking patients with non-smoking controls or when comparing smoking and non-smoking patients. Urine recoveries did not correlate with number of cigarettes or disease extent. Smoking was more prevalent in patients with a more limited disease extent (p = 0.033).
CONCLUSIONS: Effects of smoking on the urine excretion of 51Cr EDTA in health were abolished by the presence of UC. The protective effects of smoking in established UC are not due to a moderating effect of smoking on intestinal permeability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659159      PMCID: PMC1727102          DOI: 10.1136/gut.42.5.656

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Intestinal permeability: functional assessment and significance.

Authors:  S Travis; I Menzies
Journal:  Clin Sci (Lond)       Date:  1992-05       Impact factor: 6.124

2.  A meta-analysis of the role of smoking in inflammatory bowel disease.

Authors:  B M Calkins
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

3.  Smoking habits in patients with inflammatory bowel disease. A case-control study.

Authors:  C Benoni; A Nilsson
Journal:  Scand J Gastroenterol       Date:  1987-11       Impact factor: 2.423

Review 4.  Immune and inflammatory function in cigarette smokers.

Authors:  P G Holt
Journal:  Thorax       Date:  1987-04       Impact factor: 9.139

5.  Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases.

Authors:  R T Jenkins; D B Jones; R L Goodacre; S M Collins; G Coates; R H Hunt; J Bienenstock
Journal:  Am J Gastroenterol       Date:  1987-11       Impact factor: 10.864

Review 6.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

7.  Does smoking tighten the gut?

Authors:  H Prytz; C Benoni; C Tagesson
Journal:  Scand J Gastroenterol       Date:  1989-11       Impact factor: 2.423

8.  Risk factors for extensive ulcerative colitis and ulcerative proctitis: a population based case-control study.

Authors:  S M Samuelsson; A Ekbom; M Zack; C G Helmick; H O Adami
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

9.  A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test.

Authors:  I Bjarnason; T J Peters; N Veall
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

10.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

  10 in total
  5 in total

Review 1.  Role of smoking in inflammatory bowel disease: implications for therapy.

Authors:  G A Thomas; J Rhodes; J T Green; C Richardson
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

2.  Smoking and inflammatory bowel diseases: what in smoking alters the course?

Authors:  A M El-Tawil
Journal:  Int J Colorectal Dis       Date:  2010-03-24       Impact factor: 2.571

Review 3.  Ulcerative colitis in smokers, non-smokers and ex-smokers.

Authors:  Guillermo Bastida; Belén Beltrán
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 4.  Novel Models of Crohn's Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells.

Authors:  Alexander Blagov; Elena B Zhigmitova; Margarita A Sazonova; Liudmila M Mikhaleva; Vladislav Kalmykov; Nikolay K Shakhpazyan; Varvara A Orekhova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 5.  The intestinal barrier: a fundamental role in health and disease.

Authors:  Maaike Vancamelbeke; Séverine Vermeire
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-06-26       Impact factor: 3.869

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.